Eli Lilly and Company has reached a settlement with Totality Medispa, a South Carolina-based medical spa, after filing lawsuits in late 2023. The agreement requires Totality Medispa to pay a monetary amount and stop misleading consumers about selling Lilly’s popular, FDA-approved, diabetes and weight-loss treatments, tirzepatide, Mounjaro® or Zepbound®.
Eli Lilly is the only authorized supplier of FDA-approved tirzepatide medicines in the U.S. and does not provide tirzepatide’s active pharmaceutical ingredient (API) to any compounding pharmacies. Any product labeled as “tirzepatide” that is not sold by Lilly is not FDA-approved and could be dangerous.
Because Eli Lilly places patient safety at the forefront, the company has been alarmed by the dangers of Totality Medispa’s products being falsely marketed as FDA-approved tirzepatide, Mounjaro®, or Zepbound®. These counterfeit products have not been reviewed by the FDA or any global regulatory bodies, posing serious health risks to patients.